Americas Immunoassays in R&D market

United states accounted for the largest market share in 2017 in the americas immunoassays in r&d market, and is expected to reach usd 1603.70 million in 2023 from usd 1002.20 million in 2017. however, latin-america is the fastest growing market, which is expected to grow at a cagr of 9.69% during the forecast period 2018 - 2023. endocrinology segment accounted for the largest market share in 2017, this market is expected to reach usd 1021.10 million in 2023 from usd 567.90 million in 2017. this market is projected to grow at a cagr of 10.41% during the forecast period from 2018 - 2023. however, endocrinology segment is the fastest growing market, which is expected to grow at a cagr of 10.41% during the forecast period 2018 - 2023. elisa segment accounted for the largest market share in 2017, this market is expected to reach usd 940.20 million in 2023 from usd 586.10 million in 2017. this market is projected to grow at a cagr of 7.79% during the forecast period from 2018 - 2023. however, enzyme linked immunospot assay elispot segment is the fastest growing market, which is expected to grow at a cagr of 10.68% during the forecast period 2018 - 2023. pharmaceutical and biotechnology companies segment accounted for the largest market share in 2017, this market is expected to reach usd 1455.10 million in 2023 from usd 892.70 million in 2017. this market is projected to grow at a cagr of 8.16% during the forecast period from 2018 - 2023. however, academic institutions and laboratories segment is the fastest growing market, which is expected to grow at a cagr of 9.36% during the forecast period 2018 - 2023. kits and reagents segment accounted for the largest market share in 2017, this market is expected to reach usd 1467.30 million in 2023 from usd 861.10 million in 2017. this market is projected to grow at a cagr of 9.21% during the forecast period from 2018 - 2023. however, kits and reagents segment is the fastest growing market, which is expected to grow at a cagr of 9.21% during the forecast period 2018 - 2023.